Jaguar Health Delays Annual Form 10-K Filing

Jaguar Animal Health ( (JAGX) ) has released a notification of late filing.

Jaguar Health, Inc. has notified regulators that it will delay filing its Form 10-K (Yearly Report) for the financial year ended December 31, 2025, via a Form 12b-25. The company’s delayed filing relates specifically to its Annual Report on Form 10-K (Yearly Report), not to any quarterly or other periodic reports.

Management cites a delay in obtaining and compiling information required for the Form 10-K (Yearly Report), including significant and material subsequent event transactions. These post year-end transactions appear complex enough that preparing complete and accurate disclosures would have required unreasonable effort and expense within the original deadline.

Jaguar Health, Inc. indicates it expects to submit the Form 10-K (Yearly Report) no later than the fifteenth calendar day after the prescribed due date. This timing is consistent with the extension allowed under SEC Rule 12b-25 for late annual filings.

The company does not anticipate any significant change in results of operations compared with the prior fiscal year, based on information available at the time of the notice. Investors should still treat any expectations about timing and results as forward-looking statements that could change once the full Form 10-K (Yearly Report) is filed.

Jaguar Health, Inc. affirms that all other required periodic reports over the past 12 months have been filed on time, suggesting ongoing baseline compliance. The notification is signed on behalf of the company by Chief Financial Officer Carol Lizak on April 1, 2026, underscoring management’s responsibility for the delayed filing and planned completion.

The most recent analyst rating on (JAGX) stock is a Hold with a $0.65 price target. To see the full list of analyst forecasts on Jaguar Animal Health stock, see the JAGX Stock Forecast page.

Spark’s Take on JAGX Stock

According to Spark, TipRanks’ AI Analyst, JAGX is a Neutral.

The score is held down primarily by weak financial performance (large ongoing losses, high leverage, and heavy cash burn) and a bearish technical setup (trading below all major moving averages with negative MACD). Corporate events provide a meaningful positive offset via non-dilutive funding and encouraging clinical progress, but not enough to overcome current financial and trend risks.

To see Spark’s full report on JAGX stock, click here.

More about Jaguar Animal Health

Jaguar Health, Inc. is a U.S. pharmaceutical company focused on developing and commercializing prescription medicines for animal and human health. The company is listed in U.S. capital markets and regularly files annual and quarterly reports with the Securities and Exchange Commission.

Average Trading Volume: 3,834,364

Technical Sentiment Signal: Sell

Current Market Cap: $1.38M

Learn more about JAGX stock on TipRanks’ Stock Analysis page.